Resistance to targeted therapies in acute myeloid leukemia

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Targeted therapies have advanced acute myeloid leukemia (AML) treatment.
• Therapy resistance remains a significant challenge, leading to inevitable relapse.
• Understanding resistance mechanisms is crucial for improving patient outcomes.

Purpose of the Study:

• To review current knowledge on resistance mechanisms to targeted therapies in AML.
• To identify specific resistance pathways for FLT3 inhibitors, IDH inhibitors, gemtuzumab-ozogamicin, and venetoclax.
• To highlight the need for strategies to overcome treatment resistance.

Main Methods:

• Literature review of current research on targeted therapy resistance in AML.
• Analysis of resistance mechanisms associated with specific drug classes.
• Synthesis of information on genetic mutations, pathway dysregulation, and cellular metabolism.

Main Results:

• Resistance to FLT3 inhibitors involves on-target mutations and pathway dysregulation; switching inhibitors may help.
• IDH inhibitor resistance can arise from metabolic changes or secondary IDH mutations, including isotype switching.
• Gemtuzumab-ozogamicin resistance is linked to CD33 variants and cytotoxin degradation.
• Venetoclax resistance mechanisms include upregulation of MCL-1/BCL-XL and metabolic alterations.

Conclusions:

• Multiple mechanisms contribute to resistance against targeted AML therapies.
• Emerging immunotherapies may introduce novel resistance forms.
• Knowledge of these mechanisms is essential for developing effective resistance-overcoming strategies.